Back to discover

Protein / target

Protein kinase C gamma type

Encoded byPRKCGP05129Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Diacylglycerol-dependent serine/threonine kinase

Strongest disease association

Leukemia, Myeloid, Acute

Via encoding gene PRKCG · Clinical evidence · score 0.54

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensiti…

View complete UniProt function annotation

Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensitivity to opiates, pain and alcohol, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. Binds and phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its function by increasing plasma membrane-associated GRIA4 expression. In primary cerebellar neurons treated with the agonist 3,5-dihyidroxyphenylglycine, functions downstream of the metabotropic glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor which plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. May be involved in the regulation of hippocampal long-term potentiation (LTP), but may be not necessary for the process of synaptic plasticity. May be involved in desensitization of mu-type opioid receptor-mediated G protein activation in the spinal cord, and may be critical for the development and/or maintenance of morphine-induced reinforcing effects in the limbic forebrain. May modulate the functionality of mu-type-opioid receptors by participating in a signaling pathway which leads to the phosphorylation and degradation of opioid receptors. May also contributes to chronic morphine-induced changes in nociceptive processing. Plays a role in neuropathic pain mechanisms and contributes to the maintenance of the allodynia pain produced by peripheral inflammation. Plays an important role in initial sensitivity and tolerance to ethanol, by mediating the behavioral effects of ethanol as well as the effects of this drug on the GABA(A) receptors. During and after cerebral ischemia modulate neurotransmission and cell survival in synaptic membranes, and is involved in insulin-induced inhibition of necrosis, an important mechanism for minimizing ischemic injury. Required for the elimination of multiple climbing fibers during innervation of Purkinje cells in developing cerebellum. Is activated in lens epithelial cells upon hydrogen peroxide treatment, and phosphorylates connexin-43 (GJA1/CX43), resulting in disassembly of GJA1 gap junction plaques and inhibition of gap junction activity which could provide a protective effect against oxidative stress (By similarity). Phosphorylates p53/TP53 and promotes p53/TP53-dependent apoptosis in response to DNA damage. Involved in the phase resetting of the cerebral cortex circadian clock during temporally restricted feeding. Stabilizes the core clock component BMAL1 by interfering with its ubiquitination, thus suppressing its degradation, resulting in phase resetting of the cerebral cortex clock (By similarity). Phosphorylates and activates LRRK1, which phosphorylates RAB proteins involved in intracellular trafficking (PubMed:36040231)

Subcellular location

CytoplasmCytoplasm, perinuclear regionCell membraneSynapse, synaptosomeCell projection, dendrite
Domains and Gene Ontology detail (42)

Domains & features

C2Protein kinaseAGC-kinase C-terminal

Gene Ontology

  • Ccalyx of Held
  • Ccell-cell junction
  • Ccytosol
  • Cdendrite
  • Cnucleus
  • Cperinuclear region of cytoplasm
  • Cplasma membrane
  • Cpostsynaptic cytosol
  • Cpostsynaptic density
  • Cpresynaptic cytosol
  • Csynaptic membrane
  • FATP binding

697 aa · 78 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingUniProt · GOCell proliferation & survivalUniProtLipid & lipoprotein metabolismUniProtKinase signallingUniProt · GO
View supporting evidence

Synaptic signalling

  • ·Synapse, synaptosome
  • ·postsynaptic cytosol
  • ·postsynaptic density
  • ·presynaptic cytosol

Cell proliferation & survival

  • ·Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-pro…

Lipid & lipoprotein metabolism

  • ·Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-pro…

Kinase signalling

  • ·Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-pro…
  • ·calcium,diacylglycerol-dependent serine/threonine kinase activity
  • ·diacylglycerol-dependent serine/threonine kinase activity
  • ·protein kinase activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Leukemia, Myeloid, Acute1 medicine
Mastocytosis1 medicine
Mastocytosis, Systemic1 medicine
Broader indication categories (1)
Neoplasms1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

midostaurin
ApprovedInhibitor

Protein kinase C (PKC) inhibitor

Indicated for Leukemia, Myeloid, Acute, Mastocytosis, Mastocytosis, Systemic, Neoplasms

Acts on a complex — shared with PRKD3, PRKCI, PRKCA +7 more · 1 of 16 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PRKCG

Gene-level evidence surfaced through the gene PRKCG that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Leukemia, Myeloid, Acute
0.67Moderately supported

Clinical evidence dominant · Open Targets 0.54

Neoplasms
0.49Limited support

Clinical evidence dominant · Open Targets 0.39

Myelodysplastic syndrome
0.40Limited support

Clinical evidence dominant · Open Targets 0.32

Neurodegenerative Diseases
0.21Preliminary

Pathway evidence dominant · Open Targets 0.30 · no direct causal or clinical evidence

View evidence synthesis (4)
Leukemia, Myeloid, AcuteModerately supported
0.67
agreement 0.520.83
Clinical98%Literature2%

Open Targets aggregate 0.54 · 2 independent evidence families

NeoplasmsLimited support
0.49
agreement 0.340.65
Clinical91%Literature9%

Open Targets aggregate 0.39 · 2 independent evidence families

Myelodysplastic syndromeLimited support
0.40
agreement 0.250.55
Clinical99%RNA expression1%

Open Targets aggregate 0.32 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary
0.21
agreement 0.030.39
Pathway92%Literature8%

Open Targets aggregate 0.30 · 2 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Leukemia, Myeloid, Acute0.54
Neoplasms0.39
Myelodysplastic syndrome0.32
Neurodegenerative Diseases0.30

Drug development

5 compounds recorded · 1 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (5)
SOTRASTAURINPhase 2
GSK-690693Phase 1
UCN-01Phase 2
MIDOSTAURINApproval
CEP-2563Phase 1

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and High-Quality Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (10)
SM · Approved DrugSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · UniProt loc med confAB · GO CC med confPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2017-09-18

    Approval: Rydapt (EMA)

    ema · regulatory · ema · via midostaurin

  2. New publication2017-07-24
    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

    Leukemia · 2018 · 109 citations · Europe PMC · via midostaurin

  3. New publication2016-06-01
    Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

    The New England journal of medicine · 2016 · 371 citations · Europe PMC · via midostaurin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.